JASPER THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
JASPER THERAPEUTICS, INC. (JSPR) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $59.48 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2021-08-16
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-06-30 was $148.16K, a 67.37% increase year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-03-31 was -$88.68K, a 5141.61% decline year-over-year.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-12-31 was $97.02K.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-09-30 was -$12.98K.
- JASPER THERAPEUTICS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $174.31K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 1 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 5 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2021-06-30 | $148.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $59.48K 10-Q · filed 2021-08-16 | $156.49K derived: sum of 3 quarters · filed 2021-08-16 | $143.51K derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2021-03-31 | -$88.68K 10-Q · filed 2021-05-24 | $8.33K derived: sum of 2 quarters · filed 2021-05-24 | -$4.65K derived: sum of 3 quarters · filed 2021-05-24 | $83.87K derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2020-12-31 | $97.02K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-24 | $84.03K derived: sum of 2 quarters · filed 2021-05-24 | $172.55K derived: sum of 3 quarters · filed 2021-08-16 | $174.31K 10-K/A · filed 2021-05-24 | ||
| 2020-09-30 | -$12.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $75.54K derived: sum of 2 quarters · filed 2021-08-16 | $77.30K 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $88.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $90.28K 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | $1.76K 10-Q · filed 2021-05-24 | |||||
| 2019-12-31 | $95.14K 10-K/A · filed 2021-05-24 | |||||
| 2019-08-30 | $1.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |